Difference between revisions of "Neuroendocrine tumors future or investigational therapies"

Jump to: navigation, search
(Mahshid)
 
(2 intermediate revisions by 2 users not shown)
Line 2: Line 2:
 
{{Neuroendocrine tumors}}
 
{{Neuroendocrine tumors}}
 
{{CMG}}
 
{{CMG}}
 
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
 
 
 
== Overview ==
 
== Overview ==
  
Line 15: Line 12:
 
[[Category:Needs content]]
 
[[Category:Needs content]]
 
[[Category:Disease]]
 
[[Category:Disease]]
[[Category:Oncology]]
 
 
[[Category:Endocrinology]]
 
[[Category:Endocrinology]]
  
 
{{WH}}
 
{{WH}}
 
{{WS}}
 
{{WS}}
 +
[[Category:Up-To-Date]]
 +
[[Category:Oncology]]
 +
[[Category:Medicine]]
 +
[[Category:Endocrinology]]
 +
[[Category:Surgery]]

Latest revision as of 03:00, 27 November 2017

Neuroendocrine tumors Microchapters

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk factors

Natural History, Complications and Prognosis

History and Symptoms

Laboratory Findings

CT scan

PET scan

Medical Therapy

Surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Future or Investigational Therapies

Therapies based on growth factor inhibitors are in the experimental stage. These inhibitors of epidermal growth factor receptors (EGFRs), of vascular endothelial growth factor receptors (VEGFRs), and of angiopoietin-related growth factor (AGF) include imatinib, sunitinib, temozolide, thalidomide, sorafenib, and panitumumab.

References


Linked-in.jpg